Search research articles
Contact Us
Filters
Showing results (231-240 of 241) with videos related to
Page
of 25
Sort By:
Environmental Science & Technology
|
May 31, 2018
Environmental and Human Health Impacts of Spreading Oil and Gas Wastewater on Roads
T L Tasker, W D Burgos, P Piotrowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
S Banerjee, G Rustin, J Paul, et al.
Investigational New Drugs
|
October 15, 2018
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens
J R Goffin, G Nicholas, M Mates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
R Garcia-Carbonero, J G Supko, R G Maki, et al.
British Journal of Cancer
|
October 13, 2006
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, et al.
The Science of the Total Environment
|
June 1, 2015
Assessment of biomarkers for contaminants of emerging concern on aquatic organisms downstream of a municipal wastewater discharge
Edyta J Jasinska, Greg G Goss, Patricia L Gillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2015
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
S Ramalingam, G Goss, R Rosell, et al.
Investigational New Drugs
|
February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
J Nehra, P A Bradbury, P M Ellis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero, J G Supko, J Manola, et al.
Page
of 25
Search research articles
Search
Showing results (231-240 of 241) with videos related to
Sort By:
Page
of 25
Environmental Science & Technology
|
May 31, 2018
Environmental and Human Health Impacts of Spreading Oil and Gas Wastewater on Roads
T L Tasker, W D Burgos, P Piotrowski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2012
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
S Banerjee, G Rustin, J Paul, et al.
Investigational New Drugs
|
October 15, 2018
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens
J R Goffin, G Nicholas, M Mates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 20, 2005
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
R Garcia-Carbonero, J G Supko, R G Maki, et al.
British Journal of Cancer
|
October 13, 2006
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, et al.
The Science of the Total Environment
|
June 1, 2015
Assessment of biomarkers for contaminants of emerging concern on aquatic organisms downstream of a municipal wastewater discharge
Edyta J Jasinska, Greg G Goss, Patricia L Gillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 23, 2015
A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)
S Ramalingam, G Goss, R Rosell, et al.
Investigational New Drugs
|
February 6, 2020
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
J Nehra, P A Bradbury, P M Ellis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 7, 2010
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors
D J Jonker, L S Rosen, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2004
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
R Garcia-Carbonero, J G Supko, J Manola, et al.
Page
of 25